等待开盘 05-19 09:30:00 美东时间
+0.140
+1.36%
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
Keefe, Bruyette & Woods analyst Bose George downgrades PennyMac Mortgage IT (NYSE:PMT) from Outperform to Market Perform and lowers the price target from $13.5 to $12.
05-08 18:54
今日重点评级关注:Citizens:维持BioCryst制药"跑赢大市"评级,目标价从25美元升至28美元;富国银行:维持曼恩凯德生物医疗"超配"评级,目标价从8美元升至10美元
05-08 12:05
PennyMac Mortgage shares are trading lower after the company reported worse-tha...
05-07 00:57
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据PennyMac Mortgage Investment Trust (PMT) 2026年第一季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **净收入表现:** 第一季度净收入为1,400万美元,摊薄后每股收益0.16美元,年化普通股股东权益回报率为4%。 **分部收入贡献:** - 信贷敏感策略部门贡献税前收入1,600万美元,年化股本回报率17% - 利率敏感策略部门贡献税前收入800万美元,年化股本回报率3% - 聚合与证券化部门税前收入1,600万美元 **投资收益:** - 有机创造的CRT投资收益1,000万美
05-06 12:05
Companies Reporting Before The Bell • Repligen (NASDAQ:RGEN) is projected to re...
05-05 19:12
今日重点评级关注:Leerink Partners:维持Camp4 Therapeutics"跑赢大市"评级,目标价从8美元升至9美元;韦德布什:维持Arcus Biosciences"跑赢大市"评级,目标价从37美元升至41美元
04-06 16:27
Piper Sandler analyst Crispin Love maintains PennyMac Mortgage IT (NYSE:PMT) with a Neutral and lowers the price target from $13.5 to $13.
04-02 21:52
PennyMac Mortgage Investment Trust (PMT) declares $0.40/share quarterly dividend, in line with previous. Forward yield 13.46% Payable April 24; for shareholders of record April 9; ex-div April 9. See ...
03-11 20:11
Real estate stocks outperformed the broader markets in January. The S&P 500 Real Estate Index Sector (SP500-60) added 2.89% in the first month of 2026, against the benchmark S&P 500's 0.89% gain. The ...
02-01 01:00